AsCNP2017 Local Organizing Committee.
Department of Pychiatry, Faculty of Medicine, Hasanuddin University.
Perintis Kemerdekaan Rd, Km. 11 Tamalanrea, RSP Building 5th Floor, Makassar
Phone/Fax +62-411-832231 | Email : [email protected]
John H. Krystal
Dr. Krystal is the Robert L. McNeil, Jr., Professor of Translational Research, Chair of the Department of Psychiatry, and Professor of Neuroscience at the Yale University School of Medicine and Chief of Psychiatry at Yale-New Haven Hospital.
He is a graduate of the University of Chicago, Yale University School of Medicine, and the Yale Psychiatry Residency Training Program. He has published extensively on the neurobiology and treatment of schizophrenia, alcoholism, PTSD, and depression. Notably, he led the discovery of the rapid antidepressant effects of ketamine in humans.
He is the Director of the NIAAA Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD. Dr. Krystal is a member of the U.S. National Academy of Medicine. Currently, he is president of the International College of Neuropsychopharmacology (CINP), a member of the NIMH National Mental Health Advisory Council, and editor of Biological Psychiatry (IF=11.212).
Kazuyuki Nakagome, M.D., Ph.D. is a Director General of National Institute of Mental Health, National Center of Neurology and Psychiatry. He obtained his Ph.D. in psychiatry at University of Tokyo in 1995.
His main interest lies in the relationship between neuro- and social cognition and social functioning outcome in patients with psychiatric disorders. Recently, he is investigating the possibility of using NIRS (near-infrared spectroscopy), which can be applied in clinical settings, as a non-invasive biological measurement of cognition, motivation, and social functioning in psychiatric populations.
Also, along with his colleagues, he established CEPD (Cognitive Enhancement in Psychiatric Disorders) conference in Japan in 2014, which was aimed to promote the dissemination of cognitive rehabilitation not only in Japan but also in other areas of Asia.
Lakshmi N. Yatham
Lakshmi N. Yatham is a Professor of Psychiatry in the Department of Psychiatry at the University of British Columbia in Vancouver, Canada. He is also the Regional Head of Psychiatry and Regional Program Medical Director for Mental Health and Addictions at Vancouver Coastal Health and Providence Healthcare. He has an executive MBA in health care from the Sauder School of Business. Dr. Yatham has held leadership positions for national and international professional organizations including the President of the International Society for Bipolar Disorders, and he is currently the Secretary for the World Federation of Societies for Biological Psychiatry. Dr. Yatham was listed in the recently published Thomson Reuter’s report on “World’s Most Influential Scientific Minds -2014” as one of the top 2 most highly cited researchers in Canada in psychiatry/psychology and 1 of the top 100 in the world.
Dr. Yatham’s major areas of research interest include neurobiology and treatment of bipolar disorder and major depression. Dr. Yatham has received a number of awards during his career including the Michael Smith Foundation Senior Scholar Award and NARSAD Young and Independent Investigator Awards for his research, Distinguished Medical Research Lecturer Award from the Faculty of Medicine at UBC, Mogen Schou Award for international education and advocacy on bipolar disorder from the International Society for Bipolar Disorders (ISBD), South Asian Forum Internationale Award for his contributions to psychiatric research in the developing world, Heinz Lehman Award as well as the Canadian College of Neuropsychopharmacology Medal for his contributions to psychopharmacology, John M Cleghorn Award for excellence in research and leadership from the Canadian Psychiatric Association, and Frank and Kupfer Award from the ISBD for distinctive contributions to the field of bipolar disorder. Dr. Yatham’s work has been funded by a number of peer-reviewed funding agencies such as the Canadian Institutes of Health Research (CIHR), Canadian Psychiatric Research Foundation, Stanley Foundation, and National Alliance for Research on Schizophrenia and Depression, USA. He was a chair of the Michael Smith Foundation Clinical Scholars Committee and has been a reviewer and a committee member of other peer reviewed funding agencies such as the Canadian Institutes of Health Research.
Dr. Yatham has a google scholar h-index of 63, and he has published close to 270 papers in peer-reviewed international journals including in high impact journals such as Molecular Psychiatry, Archives of General Psychiatry, American Journal of Psychiatry, World Psychiatry, Biological Psychiatry and British Journal of Psychiatry. He has edited books and written a number of book chapters including a chapter on Treatment of mood disorders for the upcoming version of the Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. Dr. Yatham is a sought out speaker and has presented his research work at numerous international conferences. He has edited journal supplements and top selling books on bipolar disorder. He co-led the development of Canadian guidelines for treatment of bipolar disorder in 1997 and his group revised the guidelines for 2005 with International Commentaries.
The CANMAT guidelines are widely used for treatment of bipolar disorder around the world as these are updated and published every 2 years in Bipolar Disorders Journal with the most recent update published in February 2013. These guidelines are highly cited with the 2009 version receiving close to 590 citations. He is the Chair of the bipolar group of the Canadian Network for Mood and Anxiety Treatments (CANMAT), and is actively involved at a national and international level in continuing medical education and public education on diagnosis and treatment of bipolar disorder for psychiatrists, family physicians, and the general public. He sits on the editorial boards of a number of journals including Bipolar Disorders, World Journal of Biological Psychiatry, Acta Neuropsychiatrica, Australia and NewZealand Journal of Psychiatry, Human Psychopharmacology etc.
Dr. Norio Ozaki, MD is Professor of Psychiatry and Chairman of the Department of Psychiatry at the Nagoya University School of Medicine, Japan. Born in Kyoto, Japan, he was educated at the Nagoya University School of Medicine, Japan. Dr Ozaki gained clinical and research experience in psychiatry at the Psychiatric Department of Nagoya University School of Medicine, Japan, the Clinical Psychobiology Branch of the National Institute of Mental Health, Bethesda, Maryland/USA, and the Psychiatric Department of the Fujita Health University School of Medicine, Japan. Two Research degrees: MD (in medicine) and PhD (in medicine).
Dr Ozaki has authored over 400 research articles. He concentrates on the biological bases of mental disorder, especially genetics. Furthermore, he has conducted studies in clinical psychiatric areas. Dr Ozaki is a frequent national and international speaker and continues to be actively involved in research activities studying schizophrenia, bipolar disorders, depressive disorders, autistic spectrum disorder, substance-related disorders, and anxiety disorders.
Dr Ozaki has served on the president of the Japanese Society of Mood Disorder, and the executive committees and advisory boards of several national and international societies, such as the World Federation of Biological Psychiatry, the Pacific Rim Association for Clinical Pharmacogenetics, the Japanese Society of Psychiatry and Neurology, the Japanese Society of Biological Psychiatry, the Japanese Society of Schizophrenia and the Japanese Society of Neuropsychopharmacology. He serves as Academic Editor of several journals, including International Journal of Neuropsychopharmacology, World Journal of Biological Psychiatry, PLoS ONE and Psychiatry and Clinical Neurosciences.
Tung Ping Su
Dr. Su graduated from National Defense Medical Center and received psychiatry residency training at the Department of Psychiatry, TVGH, where he was appointed as attending physician after training. In 1983, Dr. Su went to the US and started his training at the Sleep Center of Baylor College of Medicine, Texas and received biochemistry and behavioral science research training at the Neuropsychiatry Institute of UCLA, California.
From 1986 through 1989, Dr. Su entered the second residency training program at the Department of Psychiatry of Medical College of Georgia. To pursue his career in academia, Dr. Su started his training at the Fellowship Research Program at National Institute of Mental Health, Bethesda from 1989 to 1996. He focused on mood disorders and male and female hormone research in the initial 2 years.
He spent another five years in studying clinical trial and brain imaging in schizophrenia. Dr. Su was then invited back to Taiwan to take the chairmanship at Department of Psychiatry of Cheng-Hsin Hospital in 1996. Two years later, he was appointed as both Chairs of the Department of Psychiatry, TVGH and Division of Psychiatry, National Yang-Ming University. During this period, he pursued his research interest to major depressive disorder, posttraumatic stress disorder, and schizophrenia using epidemiology, brain imaging and endocrinology approaches. In 2006, He was granted as Professor in Psychiatry to address his academic performance. He was then appointed as Vice Superintendent of TVGH, spending two years in administrative work before he retired in 2012.
Dr. Su has continued his teaching, administration and research while held his academic Chair position at Division of Psychiatry, National Yang-Ming University up until now. He introduced new concept of diagnosis of bipolar disorders and new strategies in the treatment of medication resistant unipolar and bipolar depression such as repetitive transcranil magnetic stimulation (rTMS) and single or repeated infusions of ketamine. Dr. Su is a member of several academic societies such as SOBP, APA, and ISBD and has also served in leadership roles in several professional societies. He was the President of Taiwanese Society of Biological and Neuropsychopharmacological Psychiatry (TSBPN). He also served as the President of Asian Society of Neuropsychopharmacology (AsCNP) from 2015 to 2016. He has published over 160 scientific papers and also wrote several chapters of psychiatric books.
Professor Eric Chen Clinical Professor Department of Psychiatry, The University of Hong Kong Professor Eric Chen is Head of the Department of Psychiatry in the University of Hong Kong. His research focuses on early intervention and treatment for psychotic disorders (including schizophrenia), as well as their underlying brain cognitive dysfunctions.
Professor Chen was educated at Oxford University and Edinburgh University. He has been leading the development of the early intervention for psychosis programme in Hong Kong (the EASY programme is one of the first comprehensive early psychosis programmes in Asia). He has also developed an innovative Master program focusing on Psychosis Studies which is first of its kind in Asia. Internationally, Professor Chen is past Vice-President of the International Early Psychosis Association and the Foundation Chairman of the Asian Network for Early Psychosis. Professor Chen holds Visiting Professorship at the Harvard Medical School and at the Institute of Mental Health, Singapore.
Professor Chen was also the Founding Chairman of the Hong Kong Schizophrenia Research Society and the Hong Kong Early Psychosis Intervention Society. Recently, Prof Chen has edited a textbook titled “Early psychosis Intervention: A Culturally Adaptive Clinical Guide”, summarising experiences of early psychosis intervention in Asia.
Prof. Takeda, MD, PhD is the chairman professor of Department of Psychiatry, Osaka University Graduate School of Medicine since 1990. He graduated from Osaka University Medical School in 1979, and has been engaged with biological psychiatry research in Osaka University, University of Florida, Baylor Medical School. With his background of neurochemistry, molecular genetics, and cell biology, his research covers from basic to clinical psychiatry.
He has published over 300 original papers in English, and over 300 review papers in psychogeriatrics, and biological and clinical psychiatry. Recent research interest covers molecular biology of Alzheimer’s disease, clinicopathology of schizophrenia, cognitive impairment in psychiatric disorders including, late life depression, PTSD and sleep disorders. Prof. Takeda is the President of International Psychogeriatric Association (IPA), and also the President of Japanese Society of Biological Psychiatry.
He serves as .a Board member of Japanese Society of Psychiatry & Neurology (JSPN), Japanese Society of Psychoneuropharmacology, Japanese Society of Dementia Research, Japanese Psychogeriatric Society, Japanese Society of Neurochemistry and many academic societies. He is the Editor-in-Chief of Psychogeriatrics (official journal of Japanese Psychogeriatric Society), Psychiatry and Clinical Neurosciences (official journal of JSPN), Japanese Journal of Psychiatry and Neurology (official journal of JSPN in Japanese), Cognition and Dementia, and Schizophrenia Frontier
Kua Ee Heok
Professor Kua was trained as a doctor in the University of Malaya in 1973. His training in Psychiatry was in Oxford University and he obtained the Membership of the Royal College of Psychiatrists (UK) in 1980 and Fellowship of the Royal College of Psychiatrists (UK) in 1992. He was awarded a scholarship for Geriatric Psychiatry training at Harvard University in 1984. Professor Kua has special interests in psychological disorders in old age including dementia and depression, and has wide clinical experiences including psychotherapy and stress management.
Brian Dean currently holds the positions of Head, The Division of Biological Psychiatry and Laboratory Head, Molecular Biology, The Florey Institute of Neuroscience and Mental Health, Parkville, Australia, Professor of Psychiatry and Neuroscience, the Department of Florey Neuroscience and Mental Health, University of Melbourne, Australia and Deputy Director of the Victorian Brian Bank Network (Psychiatry).
Brian Dean initially trained in the fields of pharmacology and parasitology whilst studying for a Higher National Diploma in Applied Biology at Sunderland University, UK. He then undertook specialist training in the field of biochemistry to qualify to be accepted as a Licentiate of the Institute of Biology by studying at the University of the Southbank, London. This was followed by studies at the University of Melbourne leading to the awarding of a Master of Science based on studies of circulating inhibitors of insulin action in the blood of patients with non-insulin dependent diabetes and a Doctoral Degree for studying the mechanism of dopamine uptake by platelets and how that process was affected in subjects with schizophrenia. Subsequently, he has carried out extensive studies to identify changes in the molecular structure in the brains of people with schizophrenia, bipolar disorder and major depressive disorders, to characterise the potential functional consequences of these changes and to understand the molecular mechanisms of action of psychotropic drugs.
Brian Dean research seeks to understand the causes of psychiatric disorders and to develop tools to assist in the clinical management of people with such disorders. Thus, among over 220 peer reviewed papers are significant works on understanding the role of muscarinic receptors in the aetiologies and treatment of schizophrenia and mood disorders, the role of cytokine-regulated pathways in the aetiologies of schizophrenia and mood disorders and on the neurobiology of suicide. In addition, his laboratory is making a significant effort in the area of biomarker discovery relevant to the diagnoses and treatment of psychiatric disorders.
Brian Dean is a Fellow of the Royal Society of Biology and is a Chartered Biologist. He has received a number of honours including presenting the University of Melbourne Beattie Smith Lecture and the ASPR Lilly Oration as well as being presented with the University of Melbourne Medal.
Brian Dean is the Treasurer of the CINP, the Secretary of the Asian College of Schizophrenia Research, a Councillor of the Asian College of Neuropsychopharmacolgy and a Board Member and Chairman of the SAC of the Rebecca Cooper Medical Research Foundation. He was the Inaugural President of Biological Psychiatry Australia and President of the Melbourne Chapter of the Society for Neuroscience. He currently serves on 6 Editorial Boards and provides Ad Hoc Reviewer for 25 Journals.
Anthony Albert Grace
Dr. Anthony A. Grace is a Distinguished Professor of Neuroscience and a Professor of Psychiatry and Psychology at the University of Pittsburgh in Pittsburgh, PA. He received his Ph.D. from Yale University School of Medicine with Dr. Benjamin S. Bunney and had postdoctoral training with Dr. Rodolfo Llinas in the Department of Physiology and Biophysics at New York University School of Medicine. Dr. Grace has been involved in translational research related to the dopamine system for over 30 years.
His early work pioneered the mode of action of antipsychotic drugs, and the identification and characterization of dopamine-containing neurons, and was the first to provide a means to quantify their activity state and pattern in a way that is the standard in the literature. His current work involves novel treatments for schizophrenia and its prevention, the role of dopamine in anhedonia and affective disorders, and the mode of action of ketamine and novel antidepressant drugs. Dr. Grace has received several awards for his research, including the William K. Warren Award for Excellence in Schizophrenia Research, the Paul Janssen Schizophrenia
Research Award and the Lilly Basic Scientist Award from the International College of Neuropsychopharmacology, the Efron Award and the Axelrod Award from the American College of Neuropsychopharmacology, the Gold Medal award from the Society of Biological Psychiatry, the Outstanding Basic Research award from the Schizophrenia International Research Society, as well as a NIMH MERIT award, a Distinguished Investigator award from the National Alliance for Research in Schizophrenia and Depression, the Judith Silver Memorial Investigator Award from the National Alliance for the Mentally Ill, a Fellow of the American Association for the Advancement of Science, and appointment as a Distinguished Professor of Neuroscience at the University of Pittsburgh.
He is also a past member of the governing council of the American College of Neuropsychopharmacology and the Schizophrenia International Research Society and is on the editorial board fornumerous leading journals in the field. Tony has made a substantial impact on the field, publishing more than 280 articles (H index 89) spanning basic and clinical research, and has been cited nearly 30,000 times. Tony is one of a handful of individuals that not only performs important basic research, but can to integrate this work into testable models relevant to the human condition.
Dr. Pierre Blier is a full professor at the University of Ottawa, Department of Psychiatry and Cellular/Molecular Medicines and the recipient of the Endowed Chair in Mood Disorders Research at the University of Ottawa Institute of Mental Health Research (IMHR). He has also been awarded the prestigious Canada Research Chair in Psychopharmacology by the Canadian Federal Government.
As a world-renowned scientist, Dr Blier has received several awards for his groundbreaking research, in
particular the Max Hamilton Award in 1998 from the International College of Neuropsychopharmacology for outstanding contributions in Psychopharmacology.
He obtained his B.Sc. from Bishop's University and a M.Sc. in Neuroscience from the Université de Montréal. Dr. Blier continued his research training throughout his medical training and obtained a Ph.D. in Neuroscience and his MD degree, both from the Université de Montréal.
After completing his clinical training, he carried out postdoctoral studies at the Laboratoire d'Étude et de Recherche Synthélabo in Paris. Dr Blier then joined the Department of Psychiatry at McGill University where he worked for 12 years, ascending through the ranks of assistant professor to full professor.
He continued his research endeavours for the next four years at the Brain Institute of the University of Florida as a tenured full professor.
Dr. Blier relocated in 2004 to the IMHR. These achievements have made Dr. Blier has delivered over 300 national and international lectures in his field, and is a well published author with over 200 papers.
He is a member of the British Psychopharmacology Association and of the European College of Neuropsychopharmacology, as well as a fellow of the Canadian, American and International Colleges of Neuropsychopharmacology.
Jun Soo Kwon
Intern and resident Seoul National University Hospital, Seoul, Republic of Korea, 1984—1988. Chief psychiatrist Capital Armed Forced General Hospital, 1988—1991. Instructor, assistant professor Seoul National University Medical College, 1991—1999.
Visiting assistant professor Harvard Medical School, Boston, 1996—1998. Associate professor Seoul National University Medical School, since 1999. Executive medical consultant VirtualMD, Seoul, since 2000.
Executive committee International Conference of Event-related Potential of the Brain, Boston, 1996—1999. Member bridging committee Korean Food & Drug Adminstn., Seoul, since 2000. Adjunct professor cognitive science program Seoul National University, since 2000.
Captain Republic of Korea Armed Forces, 1988-1991, Seoul.
Dr. Jun Soo Kwon has a strong interest in neuroscience, with specific emphasis on an integrative (combining genetic, neuropsychological and neuroimaging methods) approach for the evaluation of neuropsychiatric disorders, including schizophrenia and obsessive-compulsive disorder, for the purpose of finding the endophenotype for each disorder. He also focuses on issues related to the early diagnosis and intervention of neuropsychiatric disorders such as schizophrenia. Dr. Kwon has published extensively in his field and holds a patent for source localization analysis of EEG/ERP using software he developed.
Professor and Chairman, Psychiatry and Neuroscience, Hiroshima University
AsCNP Honorary President
ICGP Former President
Dr. Shigeto Yamawaki graduated from School of Medicine, Hiroshima University, Japan in 1979. He has been Professor and Chairman of the department of Psychiatry and Neurosciences, Hiroshima University since he was appointed in 1990 as a record of the youngest professor of Psychiatry in Japan. He is a board member of the Hiroshima University and the National Center of Neurology and Psychiatry (NCNP) in Japan and a member of the Science Council.
He currently serves as President (2014-2016) of the International College of Neuropsychopharmacology (CINP) and Past-President (2010-2014) of the Japanese Society of Neuropsychopharmacology (JSNP). He also served as President (2006-2008) of the International College of Geriatric Psychoneuropharmacology (ICGP), and as a founding President (2008-2010) of the Asian College of Neuropsychopharmacology (AsCNP).
The major focus of his research is on the neurobiology and clinical psychopharmacology of mood disorders. His recent interest includes the molecular basis of early adverse life events on vulnerability for major depression, the neuroimaging study on mood regulation using a visual emotion task and a future reward prediction task and the innovative neuroscience application to manufacturing technology collaborated with a car manufacturer, MAZDA.
He has published more than 300 papers in the high impact international journals such as Nature Neuroscience, Biological Psychiatry, Journal of Neuroscience, Neuroimage as well as International Journal of Neuropsychopharmacology, an official journal of CINP.